Download Medical Notes on Diabetes Costs and Affordability in the United States

Diabetes Costs and Affordability in the United States Medical Notes

About This Presentation

Description:This report titled, “Diabetes Costs and Affordability in the United States” by the IQVIA Institute provides a detailed analyses around diabetes drug pricing, including list price, net manufacturer price, and out-of-pocket costs for patients as a function of various insurance programs. The report also looks at prescription abandonment related to out-of-pocket costs, and how these costs can interrupt a patient’s ability to pay. The report examines the impact of insurance coverage and finds that commercially-insured patients have higher initial cost exposure than Medicare patients, but can use coupons to offset costs and a significant proportion are doing so, such that their final out-of-pocket costs are similar to that of Medicare patients. Finally, the report details current U.S. policies and other shifts in the diabetes landscape that will impact diabetes spending over the next few years

Tags:Diabetes Costs, Diabetes, United States, diabetes drug, pricing, healthcare, medical, insurance programs, prescription abandonment, Medicare patients

Published on: Jul 20, 2020 | Views : 1011 | Downloads : 0

Comment

Transcript

No transcript available for this presentation

User Presentation
Related Presentations

About : I am a passionate medical marketing professional with hands on experience in healthcare digital marketing.
Occupation : Medical Professional
Specialty : Other Health Professionals
Country : India
Website :

Epigenetics

REJUVENATION MEDICINE

Scientific Evidence of Activating Human Communication by Robots

Diabetes Costs and Affordability in the United States

Advancing Human Data Science - A NEW APPROACH TO IMPROVING HUMAN HEALTH OUTCOMES

Tuberculosis

Global pharma and Indian pharmaceutical industry: Prospects for growth

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2019

EvaluatePharma pharmaceutical industry world review 2019 and outlook 2024

Biopharma Companies Join Forces to Fight COVID-19

HEALTH A TO Z